Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Curr Pain Headache Rep ; 25(11): 73, 2021 Nov 11.
Article in English | MEDLINE | ID: covidwho-1527506


PURPOSE OF REVIEW: Headache is a common symptom of COVID-19 with emerging literature being published on the subject. Although it may seem unspecific, scientific evidence has allowed a better definition of this headache type, revealing relevant associations with other COVID-19 symptoms and prognoses. We therefore sought to highlight the most remarkable findings concerning headache secondary to COVID-19, specifically focusing on epidemiology, characteristics, pathophysiology, and treatments. RECENT FINDINGS: The real prevalence of headache as a symptom of COVID-19 is still unclear ranging from 10 to 70%. Headache mainly has a tension-type-like phenotype, although 25% of individuals present with migraine-like features that also occur in patients without personal migraine history. This finding suggests that a likely pathophysiological mechanism is the activation of the trigeminovascular system. SARS-CoV-2 neurotropism can occur by trans-synaptic invasion through the olfactory route from the nasal cavity, leading to anosmia which has been associated with headache. SARS-CoV-2 protein has been found not only in olfactory mucosa and bulbs but also in trigeminal branches and the trigeminal ganglion, supporting this hypothesis. However, other mechanisms such as brain vessels inflammation due to SARS-CoV-2 damage to the endothelium or systemic inflammation in the context of cytokine storm cannot be ruled out. Interestingly, headache has been associated with lower COVID-19 mortality. No specific treatment for COVID-19 headache is available at present. Studies show that investigating COVID-19 headache represents an opportunity not only to better understand COVID-19 in general but also to advance in the knowledge of both secondary and primary headaches. Future research is therefore warranted.

COVID-19/epidemiology , Headache/epidemiology , Anosmia/physiopathology , COVID-19/complications , COVID-19/mortality , COVID-19/physiopathology , Endothelium, Vascular , Headache/etiology , Headache/physiopathology , Headache/therapy , Humans , Inflammation , Migraine Disorders/physiopathology , SARS-CoV-2 , Tension-Type Headache/physiopathology , Trigeminal Ganglion/physiopathology , Trigeminal Ganglion/virology , Trigeminal Nerve/physiopathology , Trigeminal Nerve/virology , Viral Tropism
J Headache Pain ; 21(1): 115, 2020 Sep 24.
Article in English | MEDLINE | ID: covidwho-791318


BACKGROUND: Since the declaration COVID-19 as a pandemic, healthcare systems around the world have faced a huge challenge in managing patients with chronic diseases. Patients with migraine were specifically vulnerable to inadequate medical care. We aimed to investigate the "real-world" impact of COVID-19 pandemic on migraine patients, and to identify risk factors for poor outcome. METHODS: We administered an online, self-reported survey that included demographic, migraine-related, COVID-19-specific and overall psychosocial variables between July 15 and July 30, 2020. We recruited a sample of patients with migraine from headache clinic registry and via social media to complete an anonymous survey. Outcomes included demographic variables, change in migraine frequency and severity during the lockdown period, communication with treating physician, compliance to migraine treatment, difficulty in getting medications, medication overuse, symptoms of anxiety and/or depression, sleep and eating habits disturbance, screen time exposure, work during pandemic, use of traditional medicine, effect of Botox injection cancellation, and overall worries and concerns during pandemic. RESULTS: A total of 1018 patients completed the survey. Of the respondents, 859 (84.3%) were females; 733 (71.9%) were aged 20 to 40 years, 630 (61.8%) were married, and 466 (45.7%) reported working during the pandemic. In comparison to pre-pandemic period, 607 respondents (59.6%) reported increase in migraine frequency, 163 (16%) reported decrease in frequency, and 105 (10.3%) transformed to chronic migraine. Severity was reported to increase by 653 (64.1%) respondents. The majority of respondents; 626 (61.5%) did not communicate with their neurologists, 477 (46.9%) reported compliance to treatment, and 597 (58.7%) reported overuse of analgesics. Botox injections cancellation had a negative impact on 150 respondents (66.1%) from those receiving it. Forty-one respondents (4%) were infected with COVID-19; 26 (63.4%) reported worsening of their headaches amid infection period. Sleep disturbance was reported by 794 (78.1%) of respondents, and 809 (79.5%) reported having symptoms of anxiety and/or depression. CONCLUSIONS AND RELEVANCE: COVID-19 pandemic had an overall negative impact on patients with migraine. Several risk factors for poor outcome were identified. Long-term strategies should be validated and implemented to deliver quality care for patients with migraine, with emphasis on psychosocial well-being.

Coronavirus Infections/epidemiology , Migraine Disorders/physiopathology , Pneumonia, Viral/epidemiology , Prescription Drug Overuse/statistics & numerical data , Adult , Analgesics/therapeutic use , Anxiety/psychology , Betacoronavirus , Botulinum Toxins, Type A/therapeutic use , COVID-19 , Communication , Depression/psychology , Female , Health Services Accessibility , Humans , Internet , Kuwait/epidemiology , Male , Middle Aged , Migraine Disorders/drug therapy , Migraine Disorders/prevention & control , Migraine Disorders/psychology , Neuromuscular Agents/therapeutic use , Pandemics , Physician-Patient Relations , Risk Factors , SARS-CoV-2 , Sleep , Sleep Initiation and Maintenance Disorders/physiopathology , Sleep Initiation and Maintenance Disorders/psychology , Surveys and Questionnaires , Young Adult